Originally Posted by
Blue Skies
I often think you need more of a medical public health background or perspective to look into the future to value FPH rather than an accounting background.
Most young company analysts would have had little appreciation of the medical implications of a respiratory pandemic like Covid & its impact on public health.
There was quite a lag before the sp responded when Covid first became an epidemic, and also an immediate drop in sp when vaccine announced as if that was going to eradicate Covid within months rather than many years & adding millions to the already huge & ever growing numbers of people with chronic respiratory issues.
To my mind its undervalued at moment & will be $40+ later this year & thats being conservative.